GO
| HSI1 | 26,160.15 | +192.17 | 226.61B |
| HSCEI1 | 9,363.94 | +63.20 | 86.65B |
| Back Zoom + Zoom - Block Traded | |
|
2025-10-24 12:18:20 INNOVENT BIO (01801.HK) announced a global strategic partnership with Japan's Takeda Pharmaceutical (4502.JP), covering several key oncology assets, including the next-generation IO cornerstone therapy IBI363, and reached licensing agreements for the in-progress projects IBI343 and IBI3001, CMBI released a research report saying. INNOVENT BIO will receive a total upfront payment of US$1.2 billion, including a US$100 million equity investment at $112.56 per share. The transaction also includes potential milestone payments, bringing the total value to US$11.4 billion, plus additional royalties. CMBI expressed anticipation for the further global development of IBI363 and IBI343. To reflect the new partnership, based on the discounted cash flow (DCF) method, the broker added its target price for INNOVENT BIO from $109.48 to $110.62, with rating kept at Buy. ~ AASTOCKS Financial News Website: www.aastocks.com | |